ALK Status Assessment with Liquid Biopsies of Lung Cancer Patients
Patients with advanced stage non-small cell lung carcinoma (NSCLC) harboring an anaplastic lymphoma kinase ALK gene rearrangement, detected from a tissue sample, can benefit from targeted ALK inhibitor treatment. However, while treatment is initially effective in most cases, relapse or progression o...
Main Author: | Paul Hofman |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-08-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/9/8/106 |
Similar Items
-
Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report
by: Yingying Zhu, et al.
Published: (2020-07-01) -
Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice
by: Paul Hofman
Published: (2021-01-01) -
Acquired ALK Resistance Mutations Identified from Liquid Biopsy in an ALK-Rearranged Squamous Cell Lung Cancer Patient Treated with Sequential ALK TKI Therapy: A Case Report
by: Yao B, et al.
Published: (2021-08-01) -
Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology
by: Paul Hofman
Published: (2017-11-01) -
NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment
by: Estela Sánchez‐Herrero, et al.
Published: (2021-09-01)